within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J06A_ImmuneSera.J06AA04_BotulinumAntitoxin;

model BotulinumAntitoxin
  extends Pharmacolibrary.Drugs.ATC.J.J06AA04;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J06AA04</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Botulinum antitoxin is an equine-derived immunoglobulin preparation used for the treatment of botulism, a rare but serious illness caused by botulinum toxin. It acts by binding to circulating toxin molecules, neutralizing their effect and limiting disease progression. The drug is used primarily in post-exposure therapy for botulism and is approved for this purpose by relevant health authorities.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data is available for botulinum antitoxin preparations (heptavalent, equine-derived) in humans. Pharmacokinetic values below are not based on primary literature but reflect expected values for large immunoglobulin proteins administered intravenously in adults.</p><h4>References</h4><ol><li><p>Raja, SM, et al., &amp; Swamy, GK (2022). First-in-Human Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Single Doses of NTM-1633, a Novel Mixture of Monoclonal Antibodies against Botulinum Toxin E. <i>Antimicrobial agents and chemotherapy</i> 66(4) e0173221–None. DOI:<a href=\"https://doi.org/10.1128/aac.01732-21\">10.1128/aac.01732-21</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35311524/\">https://pubmed.ncbi.nlm.nih.gov/35311524</a></p></li><li><p>Guptill, JT, et al., &amp; Swamy, GK (2021). Safety, Tolerability, and Pharmacokinetics of NTM-1632, a Novel Mixture of Three Monoclonal Antibodies against Botulinum Toxin B. <i>Antimicrobial agents and chemotherapy</i> 65(7) e0232920–None. DOI:<a href=\"https://doi.org/10.1128/AAC.02329-20\">10.1128/AAC.02329-20</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33875433/\">https://pubmed.ncbi.nlm.nih.gov/33875433</a></p></li><li><p>Nayak, SU, et al., &amp; Zenilman, JM (2014). Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A. <i>Antimicrobial agents and chemotherapy</i> 58(9) 5047–5053. DOI:<a href=\"https://doi.org/10.1128/AAC.02830-14\">10.1128/AAC.02830-14</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24913160/\">https://pubmed.ncbi.nlm.nih.gov/24913160</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end BotulinumAntitoxin;
